JPRN-UMIN000020185
Completed
N/A
Effects of dapagliflozin on renal function in patients with type 2 diabetes [Diamond study-4] - Effects of dapagliflozin on renal function [Diamond study-4]
Diamond study group0 sites15 target enrollmentDecember 14, 2015
Conditionspatients with type 2 diabetes
Overview
- Phase
- N/A
- Intervention
- Not specified
- Conditions
- patients with type 2 diabetes
- Sponsor
- Diamond study group
- Enrollment
- 15
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •Patients who meet one of the following criteria are ecluded. 1\. Patients treated with insulin 2\. Patients with unstable angina 3\. Patients with severe liver dysfunction (AST \>\= 100IU/L or ALT \>\= 100IU/L) 4\. Patients with severe renal dysfunction (eGFR \< 45 mL/min/1\.73m2\) 5\. Known hypersensitivity to dapagliflozin 6\. Patients who are pregnant, possibly pregnant, or nursing 7\. A history of traetment with SGLT2 inhibitors including dapagliflozin 8\. Patients disqualified by doctor for any reason
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
N/A
Effect of Dapagriflozin on renal dysfunction in patients with heart failurechronic heart failureJPRN-UMIN000044902Mitsui Memorial Hospital100
Recruiting
Phase 4
Effect of empagliflozin on renal events in non-diabetic chronic kidney disease patientsChronic kidney disease.Chronic kidney disease (CKD)IRCT20211104052965N1Shahid Beheshti University of Medical Sciences458
Active, Not Recruiting
Phase 1
The effect of treatment with Dapagliflozin on heart and kidney function after catheter based aortic valve replacement for aortic stenosisPatients with aortic stenosis undergoing trans catheter aortic valve replacement.MedDRA version: 20.0Level: LLTClassification code 10058186Term: Aortic valve stenosis and insufficiencySystem Organ Class: 100000004849Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14]EUCTR2021-004271-14-DKAarhus University Hospital, department of Cardiology104
Active, Not Recruiting
Phase 1
Effect of Dapagliflozin on myocardial and renal function following aortic valve stenosis interventioAortic stenosisTherapeutic area: Diseases [C] - Cardiovascular Diseases [C14]CTIS2024-514868-11-00Aarhus Universitetshospital106
Active, Not Recruiting
Phase 1
Effect of the dapagliflozin drug on the glomerular hyperfiltration in nondiabeticobese patients.This study aims to demonstrate the hypothesis that treatment with dapagliflozin 10mg lowers in at least 10-20% of measured glomerular filtration rate (mGFR) in non-diabetic obese patients with glomerular hyperfiltration.Therapeutic area: Diseases [C] - Symptoms and general pathology [C23]EUCTR2019-002262-12-ESHospital Universitari Germans Trias i Pujol60